Cytisinicline smoking cessation PDUFA preview: first new pharmacotherapy in 20 years

On June 20, 2026, the FDA is expected to decide on the New Drug Application (NDA) for cytisinicline, a plant-derived alkaloid developed by Achieve Life Sciences for the treatment of nicotine dependence in adults. If approved, cytisinicline would be the first new pharmacotherapy for smoking cessation since varenicline (Chantix) was approved in 2006 — a 20-year gap.

The NDA is supported by two positive Phase 3 trials (ORCA-2 and ORCA-3). Separately, the FDA granted Breakthrough Therapy designation for cytisinicline in the vaping cessation indication (based on the Phase 2 ORCA-V1 trial), and awarded the Commissioner's National Priority Voucher for vaping cessation in October 2025. ICER published a cost-effectiveness review in February 2026 with a placeholder price of $5,000 for a 12-week course.

This preview maps the evidence, regulatory timeline, pricing landscape, and what payer teams should prepare for. It is independent information and not medical advice.

Quick answer

Who this is for

• Payer pharmacy directors and medical directors preparing formulary reviews for a potential new smoking cessation drug
• Smoking cessation clinic directors and pulmonologists evaluating a new therapeutic option
• Benefits consultants and employer-plan sponsors assessing coverage design for tobacco cessation
• Market access teams at Achieve Life Sciences and competing smoking cessation products
• Public health professionals tracking the first new smoking cessation pharmacotherapy in 20 years

Source standard

Every fact in this guide is sourced from the Achieve Life Sciences NDA acceptance announcement, the FDA PDUFA date assignment, the ORCA-2 and ORCA-3 trial data, the ICER cost-effectiveness review dated February 2026, and the FDA Commissioner's National Priority Voucher announcement. Always verify current regulatory status and pricing through official channels.

Why this matters

Smoking remains the leading preventable cause of disease and death in the United States. The CDC reports that nearly 16 million US adults have been diagnosed with COPD, and approximately 80% of COPD deaths are attributed to smoking. Despite available treatments, quit rates with current pharmacotherapy remain modest, and many smokers cycle through multiple quit attempts without success.

If approved, cytisinicline would add a new mechanism to a pharmacotherapy toolbox that has not changed in two decades:

Evidence: ORCA-2 and ORCA-3

The NDA is supported by data from over 2,000 participants across two pivotal Phase 3 trials:

ORCA-2 (NCT04576949)

• Design: Randomized, double-blind, placebo-controlled
• Population: Adults who smoked ≥10 cigarettes per day
• Arms: Cytisinicline 3 mg TID for 6 or 12 weeks vs placebo, all with behavioral support
• Primary endpoint: Continuous abstinence rate (CAR) during weeks 9–12 (6-week arm) and weeks 9–24 (12-week arm)
• Result: Cytisinicline significantly increased continuous smoking abstinence compared with placebo
• Safety: Most common adverse events were insomnia, abnormal dreams, headache, and nausea

ORCA-3 (NCT05206370)

• Design: Randomized, double-blind, placebo-controlled
• Population: Adults who smoked ≥10 cigarettes per day
• Result: Cytisinicline significantly improved smoking abstinence rates compared with placebo
• Subgroup: COPD patients achieved quit rates comparable to non-COPD patients, supporting cytisinicline as an option for smokers with COPD

Mechanism

Cytisinicline is a plant-derived alkaloid (from the seeds of Laburnum anagyroides) that acts as a partial agonist and antagonist at nicotinic acetylcholine receptors, particularly the α4β2 subtype:

• As a partial agonist: Reduces nicotine craving and withdrawal symptoms by partially stimulating the receptor
• As an antagonist: Blocks nicotine from binding, reducing the reward and satisfaction from smoking

This is essentially the same mechanism of action as varenicline (Chantix), but cytisinicline is a naturally derived compound with a long history of use in Eastern Europe, where it has been used for smoking cessation for over 50 years.

Regulatory timeline and risk factors

Potential delay risk

Achieve Life Sciences disclosed in its 10-K filing that one third-party manufacturer named in the NDA recently underwent an FDA cGMP inspection, and FDA made two observations related to solid oral dose manufacturing. While these observations are being addressed through a remedial action plan, there is potential for a delay beyond the June 20 PDUFA date. The company has also partnered with a US-based manufacturer (Adare) for potential commercial supply.

ICER review and pricing

The Institute for Clinical and Economic Review (ICER) published its review in February 2026:

• Placeholder price: $5,000 for a 12-week course (actual price not yet disclosed)
• Cost-effectiveness vs behavioral support alone: Meets commonly used thresholds at the placeholder price
• Cost-effectiveness vs varenicline: Substantially exceeds cost-effectiveness thresholds at $5,000, because varenicline is available as a generic and priced much lower
• ICER voting: The evidence was not adequate to demonstrate that cytisinicline's net health benefit is greater than varenicline with behavioral support
• Policy recommendation: ICER recommended that payers cover cytisinicline without restrictive prior authorization, given the substantial unmet need in smoking cessation and relevance to health equity

ICER coverage criteria recommendations

• Age 18+
• Clinical eligibility: adults who smoke cigarettes and are interested in quitting
• No exclusion for serious mental illness (unlike some varenicline policies)
• Exclusion: end-stage renal disease, pregnancy, breastfeeding
• No provider restrictions recommended

Payer access considerations

If approved, payer teams should prepare for several formulary decisions:

Formulary positioning

• Therapeutic class: Smoking cessation agents — currently dominated by OTC nicotine replacement and generic varenicline
• Potential tier placement: Tier 2 or Tier 3 (branded, with PA) depending on pricing
• Step therapy: Payers may require trial of NRT or varenicline before cytisinicline, given the ICER finding that cytisinicline does not demonstrate superior efficacy vs varenicline
• Quantity limits: 12-week supply maximum per quit attempt, consistent with clinical trial duration

Prior authorization criteria (anticipated)

• Diagnosis of nicotine dependence (ICD-10: F17.210)
• Documented interest in quitting smoking
• May require trial and failure of varenicline or NRT (step therapy)
• May exclude patients with end-stage renal disease, pregnancy, or breastfeeding
• One approval per 12-month period

Employer and plan sponsor considerations

• Essential health benefit: Smoking cessation is a preventive service under the ACA, and plans must cover it without cost-sharing
• Employer demand: Employers have strong financial incentives to support smoking cessation — the CDC estimates smoking costs employers over $5,800 per smoker per year in lost productivity and excess medical costs
• Equity considerations: ICER noted that smoking disproportionately affects populations that have not been equitably served by the healthcare system, supporting broad coverage without barriers

Competing products

Vaping cessation potential

In October 2025, the FDA awarded cytisinicline for vaping cessation the Commissioner's National Priority Voucher. Key points:

• There are currently no FDA-approved therapies indicated specifically for e-cigarette or vaping cessation
• Achieve Life Sciences completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with FDA for a future vaping indication
• The vaping indication would be pursued separately from the initial smoking cessation NDA

What to monitor

• PDUFA outcome: Whether FDA approves on June 20, 2026, issues a Complete Response Letter, or delays the decision
• Launch pricing: Achieve Life Sciences' pricing strategy will determine formulary access; a price closer to generic varenicline would facilitate broader adoption
• Step therapy policies: Whether payers require varenicline failure before covering cytisinicline will be the key access battleground
• Vaping indication: The Commissioner's National Priority Voucher for vaping cessation could accelerate a second indication
• Real-world differentiation: Whether the "natural, plant-based" positioning drives uptake among patients who declined varenicline
• Manufacturer readiness: Whether the cGMP observations at the third-party manufacturer are resolved in time for launch

Sources

• Achieve Life Sciences. FDA Acceptance of Cytisinicline NDA. Press release. September 3, 2025. Available at: https://ir.achievelifesciences.com/news-events/press-releases/detail/238/achieve-life-sciences-announces-fda-acceptance-of-cytisinicline-new-drug-application-for-treatment-of-nicotine-dependence-for-smoking-cessation
• Achieve Life Sciences. FDA Commissioner's National Priority Voucher for Cytisinicline for Vaping Cessation. Press release. October 17, 2025. Available at: https://ir.achievelifesciences.com/news-events/press-releases/detail/243/achieve-life-sciences-receives-fda-commissioners-national-priority-voucher-for-cytisinicline-for-treatment-of-nicotine-dependence-for-e-cigarette-or-vaping-cessation
• The Cardiology Advisor. FDA Drug Approval Decisions Expected in June 2026. Available at: https://www.thecardiologyadvisor.com/news/fda-drug-approval-decisions-expected-in-june-2026
• ICER. Cytisinicline for Smoking Cessation: Report at a Glance. February 2026. Available at: https://icer.org/wp-content/uploads/2026/02/ICER_Smoking-Cessation_RAAG_For-Publication_021226.pdf
• ICER. Cytisinicline for Smoking Cessation: Final Policy Recommendations. February 2026. Available at: https://icer.org/wp-content/uploads/2026/02/ICER_Smoking-Cessation-Policy-Recommendations_For-Publication_021226.pdf
• BioSpace. Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline. October 2025. Available at: https://www.biospace.com/press-releases/achieve-life-sciences-receives-fda-commissioners-national-priority-voucher-for-cytisinicline-for-treatment-of-nicotine-dependence-for-e-cigarette-or-vaping-cessation
• Psychiatric Times. FDA Accepts New Drug Application for Cytisinicline for Smoking Cessation. September 2025. Available at: https://www.psychiatrictimes.com/view/fda-accepts-new-drug-application-for-cytisinicline-for-smoking-cessation
• Respiratory Therapy. Positive Data for Smoking Cessation Drug Candidate. 2026. Available at: https://respiratory-therapy.com/products-treatment/pharmaceuticals/us-pharmaceuticals/positive-data-for-smoking-cessation-drug-candidate
• ClinicalTrials.gov. NCT04576949: A Phase 3 Study of Cytisinicline for Smoking Cessation (ORCA-2). Available at: https://clinicaltrials.gov/ct2/show/NCT04576949
• ClinicalTrials.gov. NCT05206370: A Phase 3 Study of Cytisinicline for Smoking Cessation (ORCA-3). Available at: https://clinicaltrials.gov/ct2/show/NCT05206370